Analysts forecast that Sientra Inc (NASDAQ:SIEN) will announce earnings per share (EPS) of ($0.76) for the current quarter, according to Zacks. Three analysts have issued estimates for Sientra’s earnings, with the lowest EPS estimate coming in at ($0.89) and the highest estimate coming in at ($0.71). Sientra reported earnings of ($0.73) per share during the same quarter last year, which would indicate a negative year over year growth rate of 4.1%. The business is expected to announce its next quarterly earnings results on Tuesday, August 6th.
According to Zacks, analysts expect that Sientra will report full year earnings of ($2.95) per share for the current financial year, with EPS estimates ranging from ($3.43) to ($2.68). For the next financial year, analysts expect that the company will report earnings of ($2.16) per share, with EPS estimates ranging from ($2.91) to ($1.51). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Sientra.
Sientra (NASDAQ:SIEN) last announced its quarterly earnings results on Wednesday, May 8th. The medical instruments supplier reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.15). The firm had revenue of $17.55 million during the quarter, compared to the consensus estimate of $17.00 million. Sientra had a negative return on equity of 119.59% and a negative net margin of 126.32%.
Several brokerages have issued reports on SIEN. Zacks Investment Research lowered Sientra from a “hold” rating to a “sell” rating in a report on Friday, April 5th. Craig Hallum set a $23.00 price objective on Sientra and gave the stock a “buy” rating in a research note on Monday, April 22nd. BidaskClub raised Sientra from a “strong sell” rating to a “sell” rating in a research note on Thursday, April 25th. Maxim Group reissued a “buy” rating and issued a $20.00 price objective on shares of Sientra in a research note on Monday, February 11th. Finally, ValuEngine downgraded Sientra from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $21.00.
Shares of NASDAQ:SIEN opened at $6.49 on Monday. The company has a market capitalization of $195.77 million, a price-to-earnings ratio of -2.00 and a beta of -0.10. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.16 and a current ratio of 1.52. Sientra has a 52-week low of $6.41 and a 52-week high of $26.79.
Institutional investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Sientra in the fourth quarter worth approximately $29,000. BNP Paribas Arbitrage SA raised its stake in shares of Sientra by 97,300.0% in the first quarter. BNP Paribas Arbitrage SA now owns 4,870 shares of the medical instruments supplier’s stock worth $42,000 after purchasing an additional 4,865 shares during the last quarter. Great West Life Assurance Co. Can purchased a new stake in shares of Sientra in the fourth quarter worth approximately $64,000. Metropolitan Life Insurance Co. NY raised its stake in shares of Sientra by 356.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 8,191 shares of the medical instruments supplier’s stock worth $104,000 after purchasing an additional 6,397 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Sientra in the fourth quarter worth approximately $135,000. 86.18% of the stock is owned by hedge funds and other institutional investors.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Featured Article: What is the Federal Reserve?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.